DECAPEPTIDE-12
Decapeptide-12 is a synthetic oligopeptide that potently inhibits tyrosinase activity, reducing melanin production in melanocyte cultures. It is under investigation as a topical agent for hyperpigmentation and skin-lightening applications in animal models.
Decapeptide-12 is a ten-residue synthetic oligopeptide with potent anti-tyrosinase activity, studied primarily for its ability to reduce melanin production and improve skin tone uniformity. In preclinical research, it has demonstrated approximately 17-fold greater efficacy than hydroquinone, the previous standard for treating hyperpigmentation.
Overview
Decapeptide-12 targets tyrosinase, a copper-containing enzyme that catalyzes the rate-limiting step in melanin biosynthesis. By reversibly binding tyrosinase, the peptide blocks the oxidation of phenolic substrates required for pigment formation. This mechanism has attracted interest from both the dermatological and cosmetics research communities as a potential approach to treating conditions such as melasma and post-inflammatory hyperpigmentation.
Beyond skin applications, tyrosinase inhibitors like Decapeptide-12 have been explored in the food industry to prevent enzymatic browning of fruits and vegetables, and in entomology as potential insecticides, given the enzyme's role in insect wound healing and exoskeleton formation.
Mechanism of Action
Decapeptide-12 reversibly binds the active site of tyrosinase, preventing it from catalyzing the oxidation of L-tyrosine and L-DOPA to dopaquinone, the committed step in melanin synthesis. In mammals, tyrosinase is localized exclusively within melanosomes of melanocytes. The enzyme's structure varies substantially across species, and in humans, skin color differences arise from polymorphisms in the TYR gene on chromosome 11 that affect tyrosinase catalytic efficiency (Iozumi et al., 1993).
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Tyrosinase Inhibition and Melanin Reduction
Studies in cultured melanocytes demonstrated that Decapeptide-12 reduces melanin content by 27-43% over 7 days of treatment. Importantly, the peptide showed selectivity for tyrosinase inhibition without significant cytotoxicity to melanocytes (Abu Ubeid et al., 2009). This short-sequence oligopeptide was identified through screening of peptide libraries for mushroom and human tyrosinase inhibitory activity.
Topical Efficacy in Photodamage
A prospective animal study evaluating topical Decapeptide-12 in photodamaged skin found dramatic reductions in hyperpigmentation. Nearly 40% of subjects achieved baseline skin tone (complete resolution of hyperpigmentation), while 15% improved from grade 3 to grade 1 photodamage. Subjects with the most severe grade 4 photodamage showed moderate improvement to grade 3 after twelve weeks (Kassim et al., 2012).
Melasma Treatment
In a split-face, randomized, double-blind, placebo-controlled pilot study, statistically significant improvements in skin tone were observed in 100% of subjects with melasma. The study demonstrated Decapeptide-12's potential as a targeted treatment for recalcitrant hyperpigmentation conditions (Hantash & Jimenez, 2009).
Safety Profile
In the clinical studies conducted to date, Decapeptide-12 has been well-tolerated when applied topically. No significant adverse effects were reported in the split-face trial or the open-label photodamage study. As a topically applied peptide, systemic absorption is expected to be minimal. Long-term safety data from large-scale trials remain unavailable.
Pharmacokinetic Profile
- Half-life
- Not established
Quick Start
- Typical Dose
- Most clinical systems utilize a concentration of 0.01% decapeptide-12.
- Route
- Topical
Molecular Structure
- Formula
- C65H90N18O17
- Weight
- 1311.46 Da
- CAS
- Not available
- PubChem CID
- 25087629
- Exact Mass
- 1394.6731 Da
- LogP
- -6.5
- TPSA
- 617 Ų
- H-Bond Donors
- 23
- H-Bond Acceptors
- 21
- Rotatable Bonds
- 42
- Complexity
- 2690
Identifiers (SMILES, InChI)
InChI=1S/C65H90N18O17/c66-24-4-3-9-45(76-55(91)47(11-6-26-73-65(70)71)77-60(96)51(32-84)81-57(93)46(10-5-25-72-64(68)69)75-54(90)43(67)27-35-12-18-39(87)19-13-35)56(92)78-48(28-36-14-20-40(88)21-15-36)58(94)82-53(34-86)62(98)83-52(33-85)61(97)79-49(30-38-31-74-44-8-2-1-7-42(38)44)59(95)80-50(63(99)100)29-37-16-22-41(89)23-17-37/h1-2,7-8,12-23,31,43,45-53,74,84-89H,3-6,9-11,24-30,32-34,66-67H2,(H,75,90)(H,76,91)(H,77,96)(H,78,92)(H,79,97)(H,80,95)(H,81,93)(H,82,94)(H,83,98)(H,99,100)(H4,68,69,72)(H4,70,71,73)
OYVFAMLECFSFEI-UHFFFAOYSA-NResearch Protocols
topical
Topical Efficacy in Photodamage A prospective animal study evaluating topical Decapeptide-12 in photodamaged skin found dramatic reductions in hyperpigmentation. Safety Profile In the clinical studies conducted to date, Decapeptide-12 has been well-tolerated when applied topically.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | Most clinical systems utilize a concentration of 0.01% decapeptide-12. | Per protocol | — |
Safety Profile
Common Side Effects
- High Tolerability:: Notable for a lack of adverse events such as redness, itching, or peeling in clinical trials.
- Non-Cytotoxic:: Unlike hydroquinone, it does not damage or kill melanocytes, making it safer for long-term use.
- Low Irritation:: Generally suitable for sensitive skin or those who cannot tolerate standard bleaching agents.
Quality Indicators
What to look for
- Well-established safety profile
Frequently Asked Questions
References (7)
- [2]Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles
→ Research indicated that decapeptide-12 is safer than hydroquinone and can reduce melanin content by over 50% after 16 weeks of twice-daily use.
- [3]Combined topical delivery and dermalinfusion of decapeptide-12 accelerates resolution of post-inflammatory hyperpigmentation in skin of color
→ Combining topical decapeptide-12 with dermalinfusion was found to safely accelerate the clearing of post-inflammatory hyperpigmentation in patients with skin of color.
- [4]Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12
→ A clinical evaluation demonstrating the safety and efficacy of decapeptide-12 when used as part of a comprehensive skin-brightening regimen.
- [5]A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma
→ Early pilot data showed decapeptide-12 significantly diminished the appearance of stubborn melasma by up to 50% over a 16-week period.
- [7]Abu Ubeid A, Zhao L, Wang Y, Hantash BM Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase J Invest Dermatol (2009)
- [6]Iozumi K, Hoganson GE, Pennella R, Everett MA, Fuller BB Role of tyrosinase as the determinant of pigmentation in cultured human melanocytes J Invest Dermatol (1993)
- [1]Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma
→ This 16-week study found that a 0.01% decapeptide-12 system reduced melasma severity by 60% and was well-tolerated in Hispanic female patients.
Davunetide (AL-108)
Davunetide (AL-108) is an intranasal formulation of the NAP peptide (NAPVSIPQ) derived from activity-dependent neuroprotective protein (ADNP), developed by Allon Therapeutics for clinical trials in schizophrenia cognitive impairment, progressive supranuclear palsy, and mild cognitive impairment.
Alpha-Defensins (HNP-1 to HNP-4, HD-5, HD-6)
Alpha-defensins are 29-35 amino acid cysteine-rich antimicrobial peptides stored in neutrophil azurophilic granules (HNP-1 to HNP-4) and Paneth cells (HD-5, HD-6), forming the first line of innate immune defense through membrane pore formation and immunomodulation.